Spain's Provital Targets the Hypodermis with Intensilk, a New Layer for Topical Skincare

The skin layer cosmetics target just got deeper. If the dermis is where collagen and elastin live, the hypodermis sits below it — the deepest layer, where adipocytes and connective tissue reside. The very idea that a topical product can meaningfully reach the hypodermis has been viewed skeptically. At in-cosmetics Global 2026 in Paris (April 14–16), Spanish ingredient maker Provital put that idea back on the table with Intensilk.

What Intensilk claims

Provital’s new active claims to target the hypodermis directly. Two core actions, per the company:

First, induce a “caloric restriction effect” in subcutaneous adipocytes.

Second, remodel the extracellular matrix (ECM) to restore skin firmness and luminosity.

It is the first attempt to bundle GLP-1 users and people concerned about cellulite into a single category and address them with one ingredient.

A new target layer

Skin has three anatomical layers: epidermis, dermis, hypodermis (subcutaneous tissue). The epidermis is roughly 0.05–1.5 mm thick, the dermis 1–3 mm, and the hypodermis ranges from 5 mm to several centimeters depending on body site and individual.

Conventional cosmetics typically reach only the upper dermis. Active molecules — peptides, retinoids, vitamin C — penetrate to varying depths within the epidermis and superficial dermis depending on molecular weight and lipophilicity. The hypodermis has been considered out of reach for topical formulations.

Provital has not detailed how Intensilk crosses this barrier. Two plausible mechanisms exist. One is indirect: signaling molecules in the dermis modulate hypodermal adipocyte activity downstream. The other is targeting the upper-hypodermal connective tissue (fibrous septae) and remodeling the ECM there.

What “caloric restriction effect” means here

The phrase “induce a caloric restriction effect” is what makes this notable. Caloric restriction normally refers to systemic dietary intervention. In a cosmetic context, it points to molecular signals at the adipocyte level — reduced fat storage, increased mitochondrial activity.

These signals usually involve sirtuin 1 (SIRT1) activation, AMPK pathway activation, and induced autophagy. In the supplement world, resveratrol, NMN, and metformin trigger similar signaling. Sending the same signals to subcutaneous adipocytes via topical application is a relatively new claim.

Provital’s positioning reads as a response to GLP-1 rebound — the rapid weight regain after stopping the drug. Regained weight rarely redistributes the way it left (faces stay hollow while abdomens fill quickly). Intensilk’s pitch is to nudge the distribution and size of subcutaneous adipocytes at the cosmetic level.

Why cellulite matters here

Intensilk’s parallel claim on cellulite matters for the market. Cellulite is medically the protrusion of subcutaneous adipocytes through fibrous septae, creating dimpled surface relief. It affects 80–90% of women in some form.

Few topical products have proved effective at meaningfully reducing cellulite over the past 30 years. Caffeine creams, retinol creams, and certain peptide formulations have dominated the market with limited clinical impact. The most effective non-surgical interventions have been radiofrequency, ultrasound, and acoustic-wave therapies.

If Intensilk truly remodels the hypodermal ECM, the cellulite market opens to a new chapter. That hinges on whether marketing claims hold up under clinical scrutiny.

Market timing

Another reason Intensilk is interesting is timing. The cellulite market has been roughly stagnant at about $1.5–2B globally, but the GLP-1 surge has injected new energy. Clinical reports describe weight loss after GLP-1 use making cellulite patterns more visible.

When adipocytes shrink, the connective tissue scaffold becomes relatively more prominent, and the stretch-and-deflate cycle deepens surface contour. The paradox is real: as you lose fat, cellulite becomes more visible.

A consumer note

If a hypodermis-targeting active like Intensilk reaches the Korean market, two checks are worth making.

First, the kind of clinical data. “X% SIRT1 activation in vitro” and “X% reduction in measured subcutaneous fat thickness in human subjects” carry very different weight. Cosmetic clinical studies typically measure volume change over 8–12 weeks.

Second, formulation strength. Whether the finished product contains the same concentration as the company’s clinical work is the central question. It is common for a recommended-use ingredient (say, 0.5–1%) to be included at 0.1%.

GLP-1 face has opened a new market category, and the depth at which cosmetics target is evolving with it. Whether that evolution stops at marketing or reaches clinical proof is a question the next year or two will answer.